Establishment of serum Heparanase concentration measurement method and its application to gynecologic cancer treatment
Establishment of serum Heparanase concentration measurement method and its application to gynecologic cancer treatment
批准号:
20591955
负责人:
AOKI Yoichi
金额:
$3.0万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2010
中文摘要
点击翻译按钮获取中文摘要
英文摘要
To establish a measurement method of serum heparanase titer, we constructed ELISA system using antiHPR1 antibody, synthesized peptide for heparanase, and biotin-labeled peptide. The ELISA for heparanase measurement worked well in the reaction of the antibody and the synthesized peptide between concentrations of 10 to 1,000 nmol/l of HPR1 peptide. The ELISA also worked well in the measurement of serum heparanase between concentrations of 1 to 100nmol/l of HPR1 peptide. We tried to measure the 22 serum samples from patients with cervical cancer, endometrial cancer and ovarian cancer, and were able to get appropriate titers of heparanase concentration in each sample. These data indicate that our ELISA system for the measurement of serum heparanase titer is applicable for a clinical setting.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Recurrent juvenile granulosa cell tumor of the ovary managed by palliative radiotherapy
姑息性放疗治疗复发性幼年性卵巢颗粒细胞瘤
DOI:
--
发表时间:
2007
期刊:
International Journal of Gynecologic Cancer
影响因子:
--
作者:
[M. Hirakawa, Y. Nagai, C. Yagi, T. Nashiro, M. Inamine, Y. Aoki]
通讯作者:
Y. Aoki
Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stage III and IV endometrial cancer.
手术后同时进行术后放疗和化疗与FIGO III 期和IV 期子宫内膜癌患者的总生存期改善相关。
DOI:
--
发表时间:
2010
期刊:
Int J Clin Oncol 15
影响因子:
--
作者:
[Nakayama K, Nagai Y, Ishikawa M, Aoki Y, Miyazaki K.]
通讯作者:
Miyazaki K.
Impressive 3 cases we enrolled in phase III study of S-1+cisplatin combination chemotherapy acompared with single agent cisplatin in stage IVB, recurrent, or persistent carcinoma of the cervix.
令人印象深刻的是,我们参加了 S-1 顺铂联合化疗与单药顺铂治疗 IVB 期、复发性或持续性宫颈癌的 III 期研究,令人印象深刻。
DOI:
--
发表时间:
2009
期刊:
影响因子:
--
作者:
[Kudaka W, Hirakawa M, Inamine M, Nagai Y, Aoki Y.]
通讯作者:
Aoki Y.
Risk factors for tumor recurrence in patients with stage III-IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy.
同期放化疗的 III-IVA 期宫颈鳞状细胞癌患者肿瘤复发的危险因素。
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[Asato K., Nagai Y, Oyakawa M, Nitta H, Okubo E, Hirakawa M, Kudaka W, Inamine M, Toita T, Aoki Y.]
通讯作者:
Aoki Y.
DOI:
10.1200/jco.2010.28.15_suppl.e15519
发表时间:
2010-05
期刊:
Anticancer research
影响因子:
2
作者:
[M. Hirakawa;Y. Nagai;T. Toita;W. Kudaka;M. Inamine;K. Ogawa;S. Murayama;Y. Aoki]
通讯作者:
M. Hirakawa;Y. Nagai;T. Toita;W. Kudaka;M. Inamine;K. Ogawa;S. Murayama;Y. Aoki
共 36 条
Heparanase expression correlates with angiogenesis and predicts tumor metastasis in endometrial cancer.
-
批准号:17591723
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:2005
-
负责人:AOKI Yoichi
-
依托单位:
Molecular mechanism of paclitaxel on CDDP resistant ovarian cancer
-
批准号:10671523
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.15万
-
财政年份:1998
-
负责人:AOKI Yoichi
-
依托单位: